BioSpace News Archive

Deals

Nordic Nanovector ASA - Registration of Share Capital Increase in the Norwegian Register of Business Enterprises

Reference is made to the stock exchange announcement regarding the successful completion of the private placement of Nordic Nanovector ASA published on 25 January 2019.

January 30, 2019
·
1 min read
University of Exeter: Common Gene Disorder Causes Serious “Stealth” Disease, but Could Be Easily Treated

The western world’s most common genetic disorder, hemochromatosis, causes far higher levels of serious disease and disability than previously thought, despite being easy to detect and treat.

January 30, 2019
·
3 min read
Business

Baylis Strengthens Global Commercialization Strategy with Senior Hire

Baylis Medical is pleased to announce that seasoned marketing executive Gloria Yee has joined Baylis as its Vice President of Marketing.

January 30, 2019
·
2 min read
Nucleix’s Bladder EpiCheck™, Urine Test for Monitoring Bladder Cancer, Chosen as Standard-of-Care by Radboud University Medical Center

Prof. Fred Witjes, Radboud University Medical Center: “Because of the exceptional, clinically-proven, high performance of Bladder EpiCheck, we can now substitute an invasive procedure for detecting recurrent bladder cancer with a simple urine test”

January 30, 2019
·
4 min read
Deals

Co-Diagnostics, Inc. Announces Elimination of Debt, Additional Capital Infusion

Transaction included $3M of preferred shares, and the elimination of $2M of debt

January 30, 2019
·
3 min read
FDA

Merck Receives Breakthrough Therapy Designation from FDA for V114, the Company’s Investigational 15-Valent Conjugate Vaccine for the Prevention of Invasive Pneumococcal Disease, in Infants, Children, and Adolescents

Merc that V114 has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for the prevention of invasive pneumococcal disease caused by the vaccine serotypes in pediatric patients 6 weeks to 18 years of age.

January 30, 2019
·
5 min read
Business

Lannett To Report Fiscal 2019 Second-Quarter Financial Results, Host Conference Call On Wednesday, February 6

Lannett Company, Inc. announced that it will report financial results for its fiscal 2019 second quarter on Wednesday, February 6, 2019, after the market closes.

January 30, 2019
·
1 min read
Policy

Sigilon Therapeutics Expands Intellectual Property Portfolio with New Patent Issued

Portfolio Covers 16 Patent Families Across Major Markets

January 30, 2019
·
2 min read
Job Trends

Castle Biosciences Announces Publication of Prospective Multicenter Study Demonstrating that its DecisionDx-Melanoma Test can Inform Sentinel Lymph Node Biopsy Decisions

Validation data from 1,421 patients published in Future Oncology

January 30, 2019
·
5 min read
Can-Fite’s Drugs’ Potential Ability to Treat Cytokine Release Syndrome in Cancer Immunotherapy Published in Scientific Journal

Can Fite’s drugs robustly inhibit the release of inflammatory mediators that induce Cytokine Release Syndrome (CRS), a potentially fatal side effect of CAR-T and other immune-oncology therapies

January 30, 2019
·
6 min read